CT-P55 (Cosentyx Biosimilar) US Phase 3 Trial Plan Amendment Approved by FDA
Celltrion's CT-P55 (Cosentyx biosimilar) US Phase 3 clinical trial plan amendment has been approved by the FDA (approval date: 2026-05-12, submission date: 2026-03-12).
The trial is a randomized, double-blind, active-controlled, Phase 3 study in 153 patients with moderate-to-severe plaque psoriasis over 56 weeks.
Objective: compare efficacy and safety of CT-P55 vs. original Cosentyx to demonstrate biosimilarity.
Disclosure includes investment risk warning: approximately 10% probability of final drug approval, and possibility of commercial plan changes.
KOSPI Filing Information
Major Management Matters Related to Investment Decision (CTP55 (Cosentics Biosimilar) Approval of Change Application for US Phase 3 Clinical Trial Plan)